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Intervention with citrus flavonoids reverses obesity and
improves metabolic syndrome and atherosclerosis in
obese Ldlr/ mice
Amy C. Burke,*,† Brian G. Sutherland,* Dawn E. Telford,*,§ Marisa R. Morrow,*
Cynthia G. Sawyez,*,§ Jane Y. Edwards,*,§ Maria Drangova,** and Murray W. Huff1,*,†,§
Molecular Medicine* and Imaging Research Laboratories,** Robarts Research Institute, Departments of
Biochemistry† and Medicine,§ University of Western Ontario, London, Ontario, Canada N6A 5B7

Abstract Obesity and its associated metabolic dysfunction
and cardiovascular disease risk represent a leading cause of
adult morbidity worldwide. Currently available pharmacological therapies for obesity have had limited success in
reversing existing obesity and metabolic dysregulation. Previous prevention studies demonstrated that the citrus flavonoids, naringenin and nobiletin, protect against obesity and
metabolic dysfunction in Ldlr/ mice fed a high-fat cholesterol-containing (HFHC) diet. However, their effects in an
intervention model are unknown. In this report, we show
that, in Ldlr/ mice with diet-induced obesity, citrus flavonoid supplementation to a HFHC diet reversed existing obesity and adipocyte size and number through enhanced energy
expenditure and increased hepatic fatty acid oxidation. Caloric intake was unaffected and no evidence of white adipose
tissue browning was observed. Reversal of adiposity was accompanied by improvements in hyperlipidemia, insulin sensitivity, hepatic steatosis, and a modest reduction in blood
monocytes. Together, this resulted in atherosclerotic lesions
that were unchanged in size, but characterized by reduced
macrophage content, consistent with a more stable plaque
phenotype. These studies further suggest potential therapeutic utility of citrus flavonoids, especially in the context of
existing obesity, metabolic dysfunction, and cardiovascular
disease.—Burke, A. C., B. G. Sutherland, D. E. Telford, M. R.
Morrow, C. G. Sawyez, J. Y. Edwards, M. Drangova, and M. W.
Huff. Intervention with citrus flavonoids reverses obesity
and improves metabolic syndrome and atherosclerosis in
obese Ldlr/ mice. J. Lipid Res. 2018. 59: 1714–1728.
Supplementary key words steatohepatitis • beta oxidation • insulin
resistance • hypolipidemic drugs • low density lipoprotein receptordeficient mice

Fat accumulation, as a result of an imbalance between
energy input and expenditure, leads to obesity, type 2
This work was supported by Canadian Institutes of Health Research Grant MOP126045 and Heart and Stroke Foundation of Canada Grant G-14-0006179 (to
M.W.H.). Additional support was provided by Canadian Diabetes Association
Doctoral Research Grant DS-3-14-4588-AB (to A.C.B.).
Manuscript received 29 May 2018 and in revised form 12 July 2018.
Published, JLR Papers in Press, July 15, 2018
DOI https://doi.org/10.1194/jlr.M087387

1714

Journal of Lipid Research Volume 59, 2018

This is an Open Access article under the CC BY license.

diabetes, cardiovascular disease, and hepatic steatosis, which
collectively represent one of the leading causes of adult
morbidity and mortality worldwide (1–3). This suggests
that restoration of functional energy homeostasis is critical
for therapeutic intervention. Despite efforts to develop
anti-obesity medications that curtail symptoms of metabolic dysfunction, drugs that have reached the market have
limited efficacy for obesity (5–8%) and many have been
withdrawn for negative side effects (3–6). Currently available therapeutics predominantly work by either reducing
caloric intake or blocking food absorption (3). Additionally, patients often regain lost weight. The treatment strategy with the most robust and lasting improvements is
gastric bypass surgery, which has shown up to 25% weight
loss at 12 years together with a 51% remission rate for type
2 diabetes (7). Presently, gastric bypass surgery as an intervention for obesity and metabolic syndrome is limited to
patients with a BMI 35 kg/m2 (8), excluding patients
with moderate obesity, although these patients often pre
sent with increased metabolic dysfunction and cardiovascular risk (9, 10). Therefore, there is urgent need for safe and
effective medical therapies for obesity and its associated
complications, including the metabolic syndrome and cardiovascular disease.
Epidemiological studies show an inverse correlation between flavonoid (a class of plant-derived polyphenols) consumption and the development of type 2 diabetes, metabolic
syndrome, and atherosclerosis (11, 12). Previous research
in our laboratory identified the citrus-derived flavonoids,
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naringenin and nobiletin, as novel therapeutics for the
prevention of metabolic syndrome and cardiovascular disease (13–17). These flavonoids have anti-inflammatory
properties, promote insulin sensitivity, and inhibit apoB100
secretion from cultured hepatocytes (16, 18–20). When extended to a mouse model of obesity, metabolic dysfunction, and atherogenesis, namely the Ldlr/ mouse fed a
high-fat cholesterol-containing (HFHC) diet, prevention
studies revealed that supplementation of the HFHC diet
with naringenin or nobiletin attenuated weight gain and
adiposity, enhanced insulin signaling, lowered plasma lipids, and prevented systemic inflammation and hepatic steatosis, resulting in slowed atherosclerosis progression
(13–17). While these studies highlight potential therapeutic utility of the citrus flavonoids, it would be more clinically relevant to assess the efficacy of these compounds in
an intervention protocol where obesity, insulin resistance,
hyperlipidemia, and atherosclerosis have been established
prior to treatment.
In the present study, we show, in Ldlr/ mice with preestablished diet-induced obesity, metabolic dysregulation,
and intermediate-stage atherosclerosis, that intervention
by the addition of either naringenin or nobiletin to a
HFHC diet not only prevented continued obesity and deterioration in symptoms of the metabolic syndrome but also
markedly reduced adipose tissue mass, normalized glucose
homeostasis, and attenuated both hyperlipidemia and
hepatic steatosis. Correction of metabolic parameters was
accompanied by a reduction in circulating blood monocytes.
Collectively, these metabolic improvements did not resolve
the size of aortic sinus atherosclerotic lesions, but plaques
in flavonoid-treated mice were characterized by reduced
macrophage and cholesterol content, consistent with lesion
regression (21, 22).

MATERIALS AND METHODS
Animals and diets
Male Ldlr/ mice on a C57BL/6 background (Jackson Laboratory, Bar Harbor, ME) were housed in pairs in standard cages at
23°C on a 12 h light and dark cycle. The animals were cared for in
accordance with the Canadian Guide for the Care and Use of
Laboratory Animals. All experimental procedures were approved
by the Animal Care Committee at the University of Western Ontario (protocol #AUP-2016-057). Mice, 10–12 weeks of age (n = 10),
were fed, ad libitum, a purified rodent chow diet (14% of calories from fat, Teklad Rodent Diet 8604; Envigo, Madison, WI)
for 24 weeks. Another group of mice (10–12 weeks of age, n = 120,
24 per group) were fed a HFHC diet (42% of calories from fat,
0.2% cholesterol, Teklad TD09268; Envigo) for 12 weeks (baseline). A subgroup of these HFHC-fed mice (n = 24) were euthanized at 12 weeks to provide baseline data for analyses that
required euthanization. The remaining mice were divided among
four different groups and, for the subsequent 12 weeks, one
group remained on the same HFHC diet (n = 24), one group remained on the HFHC diet supplemented with 3% naringenin
(#N5893; Millipore-Sigma) (n = 24), one group remained on the
HFHC diet supplemented with 0.3% nobiletin (#10236-47-2; R&S
PharmChem, Hangzhou City, China) (n = 24), and one group was
switched to the standard rodent chow (n = 24). Food intake and

body weights were measured weekly. Caloric intake was calculated
as weight of food eaten (grams) per day multiplied by the caloric
content of each diet (chow 3.0 kcal/g; HFHC 4.5 kcal/g). We
previously observed a taste aversion with naringenin and nobiletin, which was mitigated by slowly increasing the flavonoid dose
over the first week of intervention to prevent significant impact on
food intake (data not shown).

Blood and tissue collection
Mice were fasted for 6 h at the start of the light cycle prior to
blood taking or euthanization. At the time of euthanization, animals were anesthetized with ketamine-xylazine [100 g/g ketamine hydrochloride (Bioniche Animal Health Canada Inc.,
Belleville, ON, Canada) and 10 g/g xylazine (Bayer Healthcare,
Animal Health Division, Bayer Inc., Toronto, ON, Canada)].
Blood was collected via cardiac puncture in syringes containing
80 l of 7% Na2-EDTA. Blood was centrifuged at 16,000 g for
10 min at 4°C to separate the plasma, which was stored at 20°C
for further use. Tissue dissections were performed via midline
incision. To dissect the heart for histological analysis, the left
ventricle was perfused with PBS containing heparin (10 units/ml)
and the right atrium was cut to drain the perfusate. The heart and
full-length aorta were dissected together. Aortae were rinsed and
cleaned using a dissecting microscope to remove any adipose tissue. Aortae were snap-frozen in liquid N2 and stored at 80°C for
mRNA and lipid measurements. The top half of the heart was
placed in OCT medium, frozen on dry ice, and stored at 80°C
for histological analyses. Small pieces of both epididymal and inguinal white adipose tissue (eWAT, iWAT) were fixed in 4% paraformaldehyde and paraffin embedded for histological analyses.
Liver, eWAT, iWAT, brown adipose tissue (BAT), and quadricep,
gastrocnemius, and soleus muscles were removed, weighed, and
snap-frozen in liquid N2 and stored at 80°C.

Metabolic cages
From 1 to 4 weeks prior to completion of the intervention
period, energy expenditure, respiratory exchange ratio (RER), food
consumption, and locomotor activity were assessed using the
Comprehensive Laboratory Animal Monitoring System (CLAMS;
Columbus Instruments, Columbus, OH). Mice were housed in
metabolic cages with free access to food and water and acclimatized for 48 h. For the subsequent 24 h, every 10 min, data on O2
consumption (VO2; milliliters per hour) and CO2 production
(VCO2; milliliters per hour) were collected. The RER was derived
from the ratio of VCO2 to VO2, and energy expenditure was
determined as (3.815 + 1.232 × RER) × VO2 and expressed as
ANCOVA-adjusted energy expenditure in kilocalories per hour.
ANCOVA adjustments to energy expenditure were made based
on body weight, which allowed for the determination of differences in energy expenditure independent of group differences
in body weight. The ANCOVA analysis performed for this work
was provided by the National Institute of Diabetes and Digestive
and Kidney Diseases Mouse Metabolic Phenotyping Centers
(MMPC; www.mmpc.org) using their Energy Expenditure
Analysis page (http://www.mmpc.org/shared/regression.aspx).
Ambulatory activity was measured as infrared beam breaks in the
X, Y, and Z axis per hour. Accumulated food consumption was
measured in grams and converted to kilocalories based on diet
composition.

Micro-computed tomography
Mice were first imaged at 12 weeks (baseline) on diet (n = 8 per
group) and regularly following intervention (weeks 14, 16, 18, 21,
and 23), as described previously (13). Whole-body composition analysis was conducted by micro-computed tomography
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(micro-CT) imaging using a Locus Ultra micro-CT scanner (GE
Healthcare) (23). Following a 4 h fast, mice were anesthetized
with 1.5% isoflurane in O2. The scan protocol consisted of an
X-ray tube voltage of 80 kVP and a current of 55.0 mA. A calibrating phantom, comprising air and water, was scanned concurrently
as a calibrator that enabled the conversion of the reconstructed
image values into CT numbers [Hounsfield units (HU)]. In a scan
time of 16 s, 1,000 views were acquired in one continuous rotation.
Images were reconstructed to an isotropic voxel size of 150 m3.
The analysis was conducted using MicroView software version
2.2 (GE Healthcare). Total adipose tissue volume was calculated
by selecting all voxels with values within a window of 225 to 60
HU and then divided into subcutaneous and visceral depots.
Subcutaneous and visceral adipose tissue depots were differentiated using the muscular abdominal wall, which is readily identifiable because of its higher density (24). The subcutaneous and
visceral adipose depots were outlined manually and the volume of
each region was calculated by MicroView as the number of voxels
falling within the threshold window multiplied by voxel volume
(150 m3).

Glucose and insulin tolerance tests
A glucose tolerance test was performed following a 6 h fast by
intraperitoneal injection with 15% glucose in 0.9% NaCl (1 g/kg
body weight) (15). Blood samples for glucose measurements
(Bayer contour blood glucose monitoring system; Bayer Healthcare) were taken up to 120 min postinjection. An insulin tolerance test was conducted following a 5 h fast by intraperitoneal
injection with insulin (0.6 IU/kg body weight; Novolin GE Toronto, Novo Nordisk, Cooksville, ON, Canada) (15). Blood samples for glucose measurements were obtained up to 60 min
postinjection. Glucose and insulin tolerance were calculated as a
percent change in blood glucose from baseline.

Tissue lipids
Lipids from liver, quadriceps, gastrocnemii, and solei, and fulllength aortae dissected free of fat and connective tissue were extracted using the method of Folch from samples stored at 80°C,
as described previously (14, 25). The [cholesteryl-1,2-3H(N)]cholesteryl oleate (PerkinElmer, Guelph, Canada; #NET746L) was
added to assess recovery. A combined 200 g/ml triolein and 200
g/ml cholesterol standard was prepared in isopropanol and aliquoted for standard curves (0–20 g). Samples and standards
were dried under N2 and a 1% Triton X-100 solution in chloroform added and left at room temperature for 1 h to solubilize.
Samples and standards were dried under N2, followed by the addition of deionized water and incubation at 37°C for 15 min. Samples were analyzed using enzymatic reagents for triglyceride (TG)
(Roche Diagnostics, Laval, Canada; TGs/glycerol blanked, #11877771
216), total cholesterol (TC) (WAKO Diagnostics, Richmond, VA;
cholesterol E (CHOD-DAOS method), #439-17501), and free
cholesterol (WAKO Diagnostics; free cholesterol (COD-DAOS)
method, #435-35801). Cholesteryl ester (CE) was determined as
the difference between TC and free cholesterol.

Plasma measurements
Plasma TG and TC were measured on a Cobas Mira S autoanalyzer (Roche Diagnostics) using calibrators and controls from
Roche Diagnostics (15). Enzymatic reagents for TG (Roche Diagnostics; TGs/glycerol blanked, #11877771 216) and cholesterol
(Roche Diagnostics; Cholesterol CHOD-PAP, #11491458-216) were
used. Fresh-EDTA plasma (50 l) was separated by fast-protein LC
(FPLC) using an AKTA purifier and a Superose 6 column (14). A
constant flow rate of 0.4 ml/min was used to collect 500 l fractions. An aliquot of each fraction was used to measure cholesterol
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and TGs enzymatically in both samples and standards on a microtiter plate with added enzymatic reagents [TG: Roche Diagnostics, TGs/glycerol blanked, #11877771 216 and TC: WAKO
Diagnostics, Cholesterol E: (CHOD-DAOS method), #439-17501].
Blood glucose was measured in whole blood using the Bayer contour blood glucose monitoring system (Bayer Healthcare, Etobicoke,
Canada) (15). Plasma insulin (ALPCO Diagnostics, Salem, NH;
mouse ultrasensitive ELISA #80-INSMSU-E01) was determined in
EDTA-plasma samples, stored at 80°C, by a mouse-specific ELISA.
Homeostasis model assessment of insulin resistance (HOMA-IR)
was calculated using the following formula, as previously described
for mice: HOMA-IR = 26 × fasting insulin level (ng/ml) × fasting
glucose level (mg/dl)/405 (26).

Liver beta oxidation
For hepatic fatty acid oxidation, fresh liver (250 mg) was homogenized in 0.1 M phosphate buffer (pH 7.2) containing 0.25 M
sucrose, 1 mM EDTA, 1 mM dithiothreitol, and 10 l/ml of protease inhibitor (Sigma-Aldrich; #P8340). Homogenates were centrifuged at 1,000 g at 4°C for 10 min. Twenty microliters of
supernatant were incubated for 30 min at 37°C with constant
shaking in 0.1 M phosphate buffer (pH 7.2) containing 150 mM
KCl, 10 mM HEPES, 5 mM Tris malonate, 10 mM MgCl2, 1 mM
carnitine, 5 mM ATP, and 2 Ci of [9,10-3H(N)]palmitic acid
(PerkinElmer; #NET043001MC) per 50 M unlabeled palmitic
acid complexed with 0.15% fatty acid-free BSA. Reactions were
stopped with 200 l of 0.6 N perchloric acid and unreacted fatty
acids extracted with hexanes. The 3H2O in the aqueous phase was
measured by liquid scintillation counting (15, 27).

Gene expression
RNA was isolated from aliquots of liver, eWAT, iWAT, BAT,
and whole aortae using Trizol reagent (Life Technologies, Mississauga, ON, Canada). Reverse transcription of 1 g total RNA was
performed using a high-capacity reverse transcription kit (Applied
Biosystems; ABI) to yield cDNA. Specific mRNA abundances
were measured by quantitative real-time PCR on an ABI ViiA 7
sequence detection system according to the manufacturer’s instructions. In the eWAT, iWAT, and BAT, mRNA quantitation
for Tnfa, Ccl2, Ccl3, Emr1, Ucp1, Cidea, Pdk4, Ppara, Lipe, and
Pnpla2 was determined. In liver, mRNA quantitation for Cpt1a,
Pgc1a, Srepf1c, Ppara, Acox1, Ccl2, Ccl3, and Tnfa was determined.
In the aorta, mRNA quantitation for Ccl3, Il1b, Ccl2, Tnfa, Emr1,
Ccr7, Abca1, and Abcg1 was determined. Samples (10 ng) of cDNA
were assayed in triplicate in 10 l reactions using a standard
curve quantitative real-time PCR protocol to calculate specific
mRNA concentrations. Expression levels for each gene were
normalized to Gapdh expression in each tissue. With the exception of Srebf1c, all primer and probe sets used were purchased as
TaqMan assays (ABI). The probe and primer sequences for
Srebf1c were designed from the known murine Srebf1 locus to
determine splice junctions. The intervening intronic sequence
was removed and primers and a probe were designed from the
resultant Srebp1c exon1c-exon2 sequence using Primer Express
2.0 software (ABI). Primers were obtained from Sigma-Genosys
and the probes labeled 5′ with 6-carboxyfluorescein (FAM) and
3′ with the quencher, MGB®, were from ABI (TaqMan assay
for mouse Srebf1c: forward primer, CAGGCCCGGGAAGTCACT;
reverse primer, GACCACGGAGCCATGGATT; probe, FAMATTTGAAGACATGCTCCA-MGB®).

Tissue histology and immunohistochemistry
Histological and morphometric analyses were performed as described previously (14, 17). eWAT was fixed in 4% paraformaldehyde for 24 h, processed, embedded in paraffin, sectioned on a

Microm HM335E microtome (Thermo Fisher Scientific), and
stained with H&E. Frozen serial sections (70–100 per heart, 10 m)
of the aortic sinus from hearts frozen in OCT, initiating anterior to the origin of the aortic valves, were prepared using a
Leica CM 3050S cryostat. For quantitation of lesion area in the
aortic sinus, sections were stained with oil red-O. Immunohistochemistry staining for macrophages by CD68 (Bio-Rad, Mississauga, Canada; MCA 1957), smooth muscle -actin (Abcam,
Toronto, Canada; polyclonal rabbit anti-smooth muscle -actin,
ab5694), and activated caspase-3 (Abcam; rabbit anti-active
caspase-3, ab4051) was performed as described previously (28).
Slides were fixed in acetone and blocked in 2% BSA (SigmaAldrich). After incubation with primary antibody, a goat biotinylated secondary antibody was used (Vector Laboratories,
Burlington, ON, Canada). Slides were then incubated in peroxidase blocking reagent, followed by incubation with the ABC reagent (ABC Elite Standard kit; Vector Laboratories). Slides were
exposed to the DAB substrate (peroxidase substrate kit; Vector
Laboratories) followed by counterstain in hematoxylin (SigmaAldrich). Photomicrographs were obtained using an Olympus
BX50 microscope and a QImaging Retiga EXi FAST camera.
Collagen fibrils were assessed using circular polarizing microscopy as described previously (28). Aortic sinus sections were
stained with picrosirius red (Polysciences, Warrington, PA) and
visualized using an Olympus BX51 microscope (Olympus Canada, Richmond Hill, Canada) equipped with circular polarizer/
interference filters, a liquid crystal compensator, a charge-coupled
device video camera, and Abrio image-processing software (Abrio
LC-Polscope; Cambridge Research and Instrumentation, Inc.,
Hopkinton, MA).
Morphometric analysis of lesion area, necrotic core area, CD68,
smooth muscle -actin, and collagen in lesions from mice from
each group was performed on serial sections. The relative area
of the atherosclerotic plaque positive for CD68, smooth muscle
-actin, or collagen was determined as the area of positive staining
divided by the area of the respective plaque. Quantitation was determined using ImageJ 1.50 software (National Institutes of
Health) for CD68, smooth muscle -actin, and collagen, or AxioVision software for lesion area and necrotic core size. To determine the relative activation of caspase-3, the number of cell nuclei
immunostained for activated caspase-3 was expressed as a percentage of the total lesion area. To ensure that a standard region
was measured in each mouse, lesion analyses began at the origin
of the aortic valves. All quantitations were performed independently by three people.

Flow cytometry
Blood and bone marrow cell analyses were performed in a separate experiment in Ldlr/ mice (n = 8 per group) using the
same induction and intervention protocol described above.
Blood leukocytes. Monocytes and neutrophils were identified
from whole blood. At euthanization, blood was collected by cardiac puncture into EDTA-lined tubes and immediately placed on
ice. For each mouse sample, 100 l of blood was used. UltraComp
eBeads (Affymetrix eBiosciences, Cedarlane, Burlington, ON,
Canada; #01-2222) were used as a single positive control, except
for the single positive control for the Vital Dye, where ArC™
amine reactive compensation bead kit was used (A10346; Life
Technologies, Burlington, ON, Canada). Fluorescence minus
one controls were performed on combined blood samples from
all mice, 100 l each. Viability was assessed using LIVE/DEAD®
fixable dead cell near-IR stain kit (L11019; Invitrogen, Life Technologies) (supplemental Table S1) in all samples after incubation for 25 min in the dark at room temperature. Cells were
stained with a cocktail of antibodies against CD45-eFluor®450
(Affymetrix eBiosciences, Cedarlane), Ly6-C/G-PerCP-Cy™5.5

(BD Biosciences, Cedarlane, Burlington, ON, Canada), and
CD115-APC (Affymetrix eBiosciences) on ice for 20 min in the
dark (supplemental Table S1), similar to previous studies (29).
Red blood cells were lysed in 1× PharmLyse (BD Biosciences) for
13 min at room temperature. The stained white blood cells were
centrifuged, washed, and resuspended in flow-buffer (HBSS +
0.1% BSA, w/v). Cells were fixed by the addition of 4% paraforhi
hi
maldehyde. Monocytes were identified as CD45 CD115 and
further identified into Ly6-Chi and Ly6-Clo; neutrophils were identified as CD45hi CD115lo Ly6-C/Ghi (Gr-1), similar to previous
studies (supplemental Fig. S1A) (29).
Hematopoietic stem cells. Hematopoietic stem and progenitor
cells from the bone marrow were analyzed by flow cytometry.
Bone marrow was harvested from femurs and tibias by flushing
with HBSS + 0.1% BSA w/v through a 70 m cell strainer. The cell
suspension was centrifuged for 5 min at 500 g at 6°C, supernatant aspirated, and the cells resuspended in 1× PharmLyse (BD
Biosciences) for 5 min. Red blood cell lysis was stopped by the
addition of excess HBSS + 0.1% BSA. Cells were once again centrifuged at 500 g for 5 min at 6°C and the supernatant aspirated.
Cells were resuspended in 1 ml HBSS + 0.1% BSA and blocked
with normal goat serum. Cells were once again centrifuged at 500
g for 5 min at 6°C and the supernatant aspirated. Bone marrow
was resuspended in 4 ml of HBSS + 0.1% BSA. For each mouse
bone marrow sample, 150 l of suspension were used. UltraComp
eBeads (Affymetrix eBiosciences; #01-2222) were used as a single
positive control, except for the single positive control for the Vital
Dye, where the ArC™ amine reactive compensation bead kit was
used (A10346; Life Technologies). Fluorescence minus one controls were done on combined samples from all mice, 150 l each.
Viability was assessed using LIVE/DEAD® fixable dead cell nearIR stain kit (L11019; Invitrogen, Life Technologies) (supplemental Table S1) in all samples after incubation for 25 min in the dark
at room temperature. Cells were stained with a cocktail of antibodies against FITC mouse hematopoietic lineage cocktail
[CD3 (17A2), CD45R (B220)(RA3-6B2), CD11b (M1/70), TER119, Ly-G6 (Gr-1) (RB6-8C5)] (Affymetrix eBiosciences), Brilliant
Violet 421™ anti-mouse CD117 (c-Kit) (Biolegend, Cedarlane),
Brilliant Violet 605™ anti-mouse Ly-6A/E (Sca-1) (Biolegend), Alexa
Fluor®700 anti-mouse CD16/32 (Affymetrix eBiosciences), and
PE anti-mouse CD34 (Biolegend) on ice for 20 min in the dark
(supplemental Table S1) similar to previous studies (29). The
stained white blood cells were centrifuged, washed, and resuspended in flow-buffer (HBSS + 0.1% BSA, w/v). Cells were fixed
by the addition of 4% paraformaldehyde. Hematopoietic stem

+
+
and progenitor cells were identified as Lin , Sca-1 , and ckit ,
while the hematopoietic progenitor subsets were separated using
antibodies to CD16/32 (FcRII/III) and CD34. Common myeloid
progenitors were identified as lin, Sca-1, ckit+, CD34hi, and
FcRII/IIIlo; granulocyte macrophage progenitors were identified
as lin, Sca-1, ckit+, CD34hi, and FcRII/IIIhi; megakaryocyte and
erythrocyte progenitors were identified as lin, Sca-1, ckit+, CD34lo,
and FcRII/IIIlo (supplemental Fig. S1B).
Flow cytometry was performed using an LSRII (for analysis)
running FACS DiVa software. All flow cytometry data were analyzed using FlowJo software (Tree Star Inc.)

Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were
performed using Sigma Plot version 14.0. A one-way ANOVA with
post hoc Tukey’s test was used to test for differences between
groups, except in the case of body weight and adiposity measured
over time where a two-way repeated measures ANOVA with post
hoc Tukey’s test was used. Significance thresholds were P < 0.05.
Significance differences are indicated by different lowercase
letters. A Student’s t-test was used to test for differences in
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ANCOVA-adjusted energy expenditure. Significant differences
(P < 0.05) are indicated by an asterisk.

RESULTS
Flavonoid intervention promotes weight loss and
attenuates adiposity
Previously, we determined that addition of either naringenin or nobiletin to a HFHC diet prevented the development of many of the disorders of the metabolic syndrome
and prevented atherosclerosis (15–17). To determine the
therapeutic utility of these flavonoids, we sought to assess
their efficacy in an intervention model where these disorders were preestablished. Mice were initially fed a HFHC
diet over 12 weeks to induce obesity, metabolic syndrome,
and intermediate atherosclerotic lesions, and establish a
disease baseline to which the efficacy of intervention was
evaluated (Fig. 1A). Subsequently, mice were divided
among four treatment groups for the subsequent 12 weeks:
one group remained on the HFHC diet; a second group
received intervention with regular mouse chow; a third
group received intervention with the HFHC diet supplemented with 3% naringenin; and the fourth group received intervention with the HFHC diet supplemented
with 0.3% nobiletin (Fig. 1A).
All mice gained weight over the initial 12 week induction
phase. Subsequently, mice that remained on the HFHC
diet increased their body weight a further 20% (Fig. 1B).
Mice that received intervention with naringenin or nobiletin, while also remaining on the same HFHC diet, lost
13% of the body weight gained during the induction
phase, a loss similar to that observed in the chow diet intervention group (Fig. 1B). Chow intervention suppressed
food intake during the first week, due to the abrupt change
in food texture, but was rapidly resolved (Fig. 1C). Intervention with the addition of naringenin or nobiletin to the
HFHC diet did not significantly reduce caloric intake
throughout the 12 weeks of intervention, suggesting that
there was no flavonoid effect on satiety or feeding behavior
(Fig. 1C).
Epididymal fat depots were increased during induction with the HFHC diet (Fig. 1D). Compared with baseline, intervention with naringenin or nobiletin reduced
epididymal fat by 29% and 44%, respectively, similar to
the fat loss in chow-intervened mice (Fig. 1D). By contrast, in mice that remained on the HFHC diet alone, epididymal fat mass increased by 28%. The same trends
were observed for inguinal adipose tissue (supplemental
Fig. S2A). In a separate study, we confirmed the intervention-induced adipose tissue reductions with the flavonoids by micro-CT (Fig. 1E, supplemental Fig. S2B).
Micro-CT showed that visceral fat volume was reduced
38–53% and subcutaneous fat volume was reduced 23–
43% by flavonoid intervention (Fig. 1E, supplemental
Fig. S2B). Importantly, lean tissue volume did not significantly change during the 12 weeks of intervention (Fig. 1F),
indicating that the intervention-induced weight loss was
driven by a reduction in adiposity.
1718
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Flavonoid intervention reduced adipose tissue
inflammation
Previous prevention studies demonstrated that naringenin attenuated adipocyte hypertrophy and adipose tissue
inflammation in HFHC-fed Ldlr/ mice (14). In the present study, compared with mice that remained on the HFHC
diet, intervention by either naringenin, nobiletin, or chow
induced a shift in epididymal adipocyte area toward smaller
adipocytes by 19, 23, and 30%, respectively (Fig. 1G). Similarly, flavonoid-treated mice had smaller adipocytes in inguinal adipose tissue (supplemental Fig. S2A). We next
measured the mRNA expression of inflammatory genes in
eWAT, iWAT, and BAT. Consistently, intervention with
naringenin or nobiletin reduced mean mRNA expressions
of Tnfa, Ccl2, and Ccl3, similar to reductions observed with
chow intervention. Although not statistically significant,
these reductions suggest a shift to resolution of obesityassociated adipose tissue inflammation (supplemental Fig.
S3A). To try to understand whether the reduction in
adiposity was due to browning or enhanced lipolysis,
the mRNA expression of known markers of adipose tissue
browning and lipolysis was measured. Treatment with nobiletin, but not naringenin or chow, increased the mean
Ucp1 mRNA expression in epididymal and inguinal adipose tissue (not significant). No intervention altered Ucp1
expression in BAT (supplemental Fig. S3B). Neither intervention with naringenin, nobiletin, nor chow affected
mRNA expression of other browning markers, Cidea, Pdk4,
and Ppara, or the lipolysis-associated genes, Lipe and Pnpla2,
in iWAT, eWAT, or BAT (supplemental Fig. S3B, C). This
suggests that the reduction in adiposity with each intervention was not likely mediated directly through browning or
enhanced lipolysis within white adipose tissue. Histological
assessment of BAT revealed that naringenin or nobiletin
intervention reduced tissue lipid accumulation similar to
intervention with chow (supplemental Fig. S3D).
Flavonoid intervention increases energy expenditure
Previous prevention studies have shown that the addition
of either flavonoid to the HFHC diet increased weightnormalized energy expenditure in mice (14, 16). Therefore,
we assessed whether flavonoid intervention would also correct obesity-associated suppressed energy expenditure. Following HFHC diet induction, intervention with either
naringenin or nobiletin increased ANCOVA-adjusted energy
expenditure in both the light and dark cycles, compared with mice that continued on the HFHC diet alone,
suggesting a compound-mediated mechanism (Fig. 2A).
The RER, which is indicative of metabolic fuel source, was
also altered by flavonoid intervention. Mice that continued
on the HFHC diet alone had a mean RER in the light cycle
of 0.82, which decreased to 0.75 in the dark cycle, indicative of fat as the primary metabolic fuel source over 24 h
(Fig. 2B). Interestingly, intervention with either flavonoid
to the HFHC diet maintained an RER 0.8 during the
dark cycle, when mice consume the majority of their daily
caloric intake (30). This indicates a shift to a combination
of carbohydrate and fat utilization in the flavonoid-treated
mice (Fig. 2B). Intervention with the chow diet increased

Fig. 1. Intervention with citrus flavonoids promotes
weight loss and decreases adiposity. Ldlr/ mice were
fed a HFHC diet for 12 weeks. Subsequently, the same
mice were treated with flavonoids added to the HFHC
diet for an additional 12 weeks. A: Structure of naringenin (Nar) and nobiletin (Nob), and study design. B:
Body weight measured weekly following intervention
after induction (n = 6–10 per group). C: Caloric intake
measured weekly during intervention (n = 6–10 per
group). D: Adiposity assessed as epididymal fat pad
weight/total body weight (n = 6–10 per group). E; Visceral and subcutaneous fat volume assessed by microCT (n = 6 per group). F: Lean tissue volume assessed
by micro-CT (n = 6 per group). G: Frequency distribution of adipocyte area in mice at the end of intervention (n = 6 per group). Inset shows mean adipocyte
area. Representative images of eWAT stained with
H&E. Scale bar is 100 m. Data represent the mean ±
SEM. Different letters are statistically different by
two-way ANOVA with post hoc Tukey test (B, C, E, F)
and one-way ANOVA with post hoc Tukey test (D, G)
(P < 0.05). N.S., not significant.

RER to 0.9 over 24 h, indicating enhanced oxidation of
carbohydrates. In mice intervened with either flavonoid,
food consumption increased by 2.5 kcal or 0.5 g per day,
selectively in the dark cycle (Fig. 2C) and without changes
in ambulatory activity (Fig. 2D). This small increase in food
intake was not likely detectable when measured every 3 days
in standard housing (Fig. 1C). Altogether, this suggests
that flavonoid intervention enhanced energy expenditure
and might induce a mild starvation response promoting
greater food intake.
Flavonoid intervention normalizes insulin sensitivity
The ability of intervention with naringenin or nobiletin
to reverse established insulin resistance was assessed. After
induction with the HFHC diet, Ldlr/ mice developed
elevated fasting plasma insulin and mild hyperglycemia
(Fig. 3A, B). Intervention with chow reversed hyperinsulinemia (61%) and modestly improved hyperglycemia
(15%). The addition of either naringenin or nobiletin to
the HFHC diet reversed hyperinsulinemia at week 24 by
50% and 54%, respectively, suggesting enhanced insulin
sensitivity despite the concomitant HFHC diet (Fig. 3A).
These significant reductions in fasting insulin levels were
accompanied by decreases in fasting glucose by intervention with naringenin (13%, trend) and nobiletin (35%)
(Fig. 3B). Temporally, improvements in fasting glucose were
observed at 6 weeks of flavonoid intervention and were

maintained up to 12 weeks (Fig. 3C). HOMA-IR calculations
showed that intervention with either flavonoid restored
HOMA-IR to similar levels observed in chow-intervened
mice (Fig. 3D). To determine whether normalized fasting insulin levels resulted in improved insulin or glucose
tolerance, both tolerance tests were performed at baseline
and after 12 weeks of intervention (Fig. 3E–J). At baseline,
all groups had similar insulin tolerance or clearance of glucose shown as change in blood glucose concentration over
time (Fig. 3E) and percent change in glucose over time
(Fig. 3F). Following intervention, the lower fasting glucose
levels in flavonoid-treated mice were accompanied by lower
insulin tolerance test area under the plasma glucose curve
[area under the curve (AUC)] (Fig. 3G), but there was no
change in the efficiency of glucose clearance over time
(Fig. 3H), suggesting that improved insulin tolerance did
not enhance glucose clearance. Intervention with chow did
not affect insulin tolerance (Fig. 3H). Similar glucose tolerance was observed in all groups following 12 weeks of induction (Fig. 3I). Intervention with the addition of either
naringenin or nobiletin to the HFHC diet or with chow
improved glucose tolerance compared with mice that remained on the HFHC diet alone (Fig. 3J). To understand
peripheral insulin sensitivity further, we assessed muscle
TG accumulation in quadriceps and gastrocnemii, which is
known to impair insulin signaling (31) (Fig. 3K, L). The accumulation of TG in both the quadriceps and gastrocnemius
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significantly lower compared with TG levels in HFHC-fed
mice at 24 weeks (Fig. 3L).

Fig. 2. Intervention with citrus flavonoids increases energy expenditure. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subsequently, the same mice were treated with flavonoids added to the
HFHC diet for an additional 12 weeks. Between weeks 8 and 12 of
intervention, mice were assessed in metabolic cages. A: ANCOVAadjusted energy expenditure (kilocalories per hour) over 24 h and
mean ANCOVA-adjusted energy expenditure in both the dark and
light periods (n = 6–8 per group). B: RER over 24 h and mean RER in
both the dark and light periods (n = 6–8 per group). C: Accumulated
food intake over 24 h and total food eaten during 24 h (n = 6–8 per
group). D: Ambulatory activity over 24 h and mean ambulatory
activity per hour (n = 6–8 per group). Data represent the mean ±
SEM. Different letters are statistically different by ANOVA with post
hoc Tukey test (P < 0.05). *Indicates statistically significant by Student’s t-test (P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not
significant.

muscles was elevated at baseline and increased further by
continuation on the HFHC diet (Fig. 3K, L). In quadriceps, intervention with naringenin, nobiletin, or chow
reversed TG accumulation from baseline (Fig. 3K). In gastrocnemii, intervention with either flavonoid or chow decreased the mean TG levels from baseline (trend), but were
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Journal of Lipid Research Volume 59, 2018

Flavonoid intervention improves fatty liver
Ldlr/ mice fed the HFHC induction diet accumulated
both hepatic TGs and cholesterol (Fig. 4A–C). Compared
with baseline, liver TG levels were reversed with intervention by either naringenin (28%), nobiletin (40%), or
chow (70%) (Fig. 4A). Compared with the HFHC diet at
24 weeks, intervention with either flavonoid or chow reduced liver TG by 58–82%. Compared with both baseline
and HFHC at 24 weeks, liver CE and free cholesterol were
lower with intervention by either naringenin (70%,
40%), nobiletin (60%, 33%), or chow (90%, 53%),
respectively (Fig. 4B, C). In prevention studies, we reported
that a primary mechanism for flavonoid-induced reductions in liver lipids and associated metabolic abnormalities
was enhanced Pgc1a- and Cpt1a-mediated fatty acid oxidation and attenuated Srebp1c-induced fatty acid synthesis
(15, 16). In the present study, intervention with the addition of either naringenin or nobiletin to the HFHC diet
reversed the HFHC diet-induced suppression of hepatic
fatty acid oxidation, increasing it by 2-fold compared with
baseline and by 1.4-fold compared with HFHC-fed mice at
24 weeks (Fig. 4D, E). This was accompanied by enhanced
liver mRNA expression of Cpt1a and Pgc1a. Improvements
in hepatic lipids with flavonoid or chow intervention were
associated with a reduction in Srebf1c mRNA expression
with naringenin (trend), nobiletin, and chow (Fig. 4E),
suggesting reduced hepatic de novo lipogenesis. Liver
weight was reduced with flavonoid treatment and there was
no effect on hepatic Acox1 and Ppara mRNA expression,
indicating that the flavonoid effects were independent of
peroxisome proliferation or activation of PPAR, consistent with our previous prevention studies (Fig. 4F; supplemental Fig. S4A, B) (16). Hepatic inflammation is also
exacerbated by high-fat feeding (14). Intervention with either flavonoid in addition to HFHC completely normalized
the mRNA expression of hepatic Ccl2, Ccl3, Tnfa, and Il1b,
consistent with decreases in hepatic lipids and improvements in hepatic function (supplemental Fig. S4C–F).
Flavonoid intervention improves hyperlipidemia
Upon HFHC diet feeding, Ldlr/ mice developed hypercholesterolemia and hypertriglyceridemia (Fig. 5A–G).
Intervention with naringenin or nobiletin supplementation
to the HFHC diet for 12 weeks reduced plasma cholesterol
(>50%) and TGs (>50%) (Fig. 5A, B). Flavonoid-mediated
plasma lipid lowering was confined to VLDL- and LDLcholesterol with no change in HDL-cholesterol levels (Fig.
5C–H). Greater VLDL- and LDL-cholesterol reductions
were observed with chow intervention (Fig. 5F, G).
Flavonoid intervention does not elicit atherosclerotic
lesion contraction
Due to the significant improvement in atherosclerotic
risk factors, we sought to determine the impact of flavonoid intervention on atherosclerosis regression. Aortic sinus
lesions were assessed after HFHC induction (baseline) and

Fig. 3. Intervention with citrus flavonoids restores glucose homeostasis. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subsequently the
same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. A: Fasting (6 h) plasma insulin levels (n = 17–20
per group). B: Fasting (6 h) blood glucose (n = 10–32 per group). C: Fasting (6 h) blood glucose in the same mice at baseline and 6 weeks
and 12 weeks of intervention (n = 11 per group). D: HOMA-IR (n = 7–12 per group). E, F: Insulin tolerance test (ITT) at baseline shown as
blood glucose concentrations (n = 4–6 per group) (E) and percent change in glucose from time = 0 (n = 6–9 per group) (F). G, H; ITT at
12 weeks intervention shown as blood glucose concentrations (n = 5–6 per group) (G) and percent change in glucose from time = 0 (n =
22–24 per group) (H). I: Glucose tolerance test (GTT) at baseline (n = 6–9 per group). J: GTT at 12 weeks intervention (n = 10–11 per
group). K, L: Muscle TG content in quadriceps (n = 8 per group) (K) and gastrocnemii and solei (n = 7–8 per group) (L). Data represent
the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin;
N.S., not significant.
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Fig. 4. Intervention with citrus flavonoids increases hepatic fatty
acid oxidation and reduces liver steatosis. Ldlr/ mice were fed a
HFHC diet for 12 weeks. Subsequently, the same mice were treated
with flavonoids added to the HFHC diet for an additional 12 weeks.
A: Hepatic TGs (n = 7–8 per group). B: Hepatic CE (n = 7–8 per
group). C: Hepatic free cholesterol (n = 7–8 per group). D: Ex vivo
hepatic fatty acid oxidation (n = 7–10 per group). E: Hepatic gene
expression (n = 12 per group). F: Liver weight (n = 22 per group).
Data represent the mean ± SEM. Different letters are statistically
different by ANOVA with post hoc Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin.

following flavonoid or chow intervention (Fig. 6A). While
intervention with chow did not induce regression of aortic
sinus lesions, their growth in size was significantly attenuated. Intervention with either citrus flavonoid to the HFHC
diet did not affect lesion size; the area of sinus lesions continued to increase at the same rate as in mice fed the HFHC
diet alone for 24 weeks (Fig. 6A). Lipid measurements in
whole aortae, dissected free from fat, revealed that the aortae of HFHC-fed mice continued to accumulate free cholesterol and CE (4-fold) compared with baseline (Fig.
6B). The addition of either flavonoid at intervention
slowed, but did not halt, the accumulation of aortic free or
esterified cholesterol (Fig. 6B). Chow intervention prevented further increases from baseline in aortic cholesterol
content. The aortic mRNA expression of the inflammatory genes, Ccl3, Tnfa, and Emr1, increased from baseline
with continued HFHC, which was not offset by flavonoid
1722
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Fig. 5. Intervention with citrus flavonoids lowers plasma lipids from
baseline. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subsequently, the same mice were treated with flavonoids added to the
HFHC diet for an additional 12 weeks. Mice were fasted for 6 h prior
to euthanization. Plasma was subjected to FPLC and lipids were measured in each fraction by enzymatic assay. A: Plasma TGs (n = 19–24
per group). B: Plasma cholesterol (C) (n = 21–24 per group). C:
Plasma TG FPLC tracing (n = 6–7 per group). D: Plasma VLDL TG
AUC calculations (n = 6–7 per group). E: Plasma cholesterol FPLC
tracing (n = 6–7 per group) F: Plasma VLDL cholesterol AUC calculations (n = 6–7 per group). G: Plasma LDL cholesterol AUC calculations (n = 6–7 per group). H: Plasma HDL cholesterol AUC
calculations (n = 6–7 per group. Data represent the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey
test (P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not significant.

intervention (Fig. 6C). Aortic mRNA of Il1b and Ccl2 were
not different from baseline in mice continued on HFHC or
with flavonoid intervention. Chow intervention tended to
halt or reverse aortic mRNA expression of all inflammatory
markers examined (Fig. 6C). Additionally, intervention
with either flavonoid did not increase the expression of
genes linked to regression and chow intervention actually
decreased the mRNA expression of Ccr7, Abca1, and Abcg1
(Fig. 6C).

/

Fig. 6. Intervention with citrus flavonoids does not attenuate lesion size but slows aortic cholesterol accumulation. Ldlr
mice were fed
a HFHC diet for 12 weeks. Subsequently, the same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks.
Aortae were dissected and the aortic sinus sectioned and analyzed histologically. A: Representative sections of the aortic sinus stained with oil
red-O and hematoxylin and lesion area quantitation (n = 12–21 per group). Scale bar is 500 m. B: Total cholesterol (TC), cholesteryl ester
CE, and free cholesterol (FC) in whole aortae (n = 6–8 per group). C: Gene expression in whole aortae (n = 6–8 per group). Data represent
the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin;
N.S., not significant.

Flavonoid intervention reduces plaque macrophages
Although there was no change in the plaque size with
flavonoid intervention, the decrease in aortic cholesterol
suggested that lesion composition may have been favorably
altered (Fig. 6A, B). After 12 weeks induction, plaques were
comprised mainly of macrophages (66%) (Fig. 7A, H).
Lesion macrophage content was reduced with intervention by naringenin (47%), nobiletin (50%), and chow
(69%) (Fig. 7A, H), consistent with the concept that depletion of macrophages is characteristic of a regressing
plaque (21). Although the percent of lesion area occupied
by macrophages was also less in mice continuing on HFHC
(23%), the decrease was greater with flavonoid or chow
intervention (Fig. 7A, H). Compared with lesions at baseline, continuation on the HFHC diet enlarged necrotic core
area (from 6% to 14%), increased the percent of apoptotic
cells (from 0.2% to 1.0%), reduced lesion smooth muscle
cells (SMCs) (from 3.5% to 1.8%), and increased lesion
collagen (from 20% to 35%) (Fig. 7B–F, Supplemental Fig.
S5). Intervention with either naringenin, nobiletin, or
chow halted the increase in necrotic core size, inhibited
the increase in apoptosis, attenuated the decrease in SMCs,
and maintained the increase in lesion collagen (Fig. 7B–F,

supplemental Fig. S5). Collectively, these interventioninduced changes in lesion composition are characteristic
of more stable lesions (Fig. 7G).
Flavonoid intervention prevents enhanced monocytosis
Reduced plaque macrophage content is phenotypically
associated with atherosclerosis regression (21, 32–34).
Reduced monocyte recruitment from the circulation has
been implicated as a mechanism contributing to regression
(29). In this study, continuation of the HFHC diet increased the number of circulating Ly6Chi monocytes (2-fold)
(Fig. 8A), the monocyte subset known to be the precursor
of lesion M1 and M2 macrophages (35). Intervention with
chow or nobiletin completely prevented the increase in Ly6Chi monocytes, while with naringenin intervention, there
was a trend to attenuation of the HFHC-induced elevation
in Ly6Chi monocytes (Fig. 8A). There was no effect on circulating Ly6Clo monocytes or total neutrophil levels with
continuation of the HFHC diet or with any intervention
(Fig. 8B, D). To investigate this trend further, bone marrow progenitor populations were measured (supplemental
Fig. S6). Intervention with chow reduced bone marrow
hematopoietic stem and progenitor cell populations, whereas
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Fig. 7. Intervention with citrus flavonoids improves lesion morphology. Ldlr/ mice were fed a HFHC diet for 12 weeks. Subsequently, the
same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. Aortae were dissected and the aortic sinus sectioned and analyzed histologically. A: Percent of lesion area occupied by CD68+ macrophages (n = 14–22 per group). B: Percent of lesion
area occupied by the necrotic core (n = 14–17). C: Percent of lesion positive for activated capase-3 (n = 9–20 per group). D: Percent of lesion
area occupied by SMCs (-actin) (n = 12–23 per group). E: Percent of lesion area occupied by collagen (picrosirius red) (n = 12–19 per
group). F: Collagen organization measured as mean collagen fibril retardation (n = 12–19 per group). G: Lesion composition for each dietary group. H: Representative histological sections of the aortic sinus stained with CD68 (macrophages) and counterstained with hematoxylin. Scale bar is 500 m. Data represent the mean ± SEM. Different letters are statistically different by ANOVA with post hoc Tukey test
(P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not significant.

the modest reductions with flavonoid intervention were
not significant (supplemental Fig. S6A, C). A similar trend
persisted when looking at bone marrow myeloid progenitor cells (supplemental Fig. S6B, C), common myeloid progenitor cells (supplemental Fig. S6D, G), and granulocyte
macrophage progenitor cells (supplemental Fig. S6E, G).
There was no consistent effect of any treatment group on
megakaryocyte and erythrocyte progenitor cells (supplemental Fig. S6F, G).

DISCUSSION
In the present study, we showed that intervention with
the citrus-derived flavonoids, naringenin or nobiletin, when
supplemented to a HFHC diet, reversed diet-induced
obesity and insulin resistance, improved hyperlipidemia
and hepatic steatosis, and favorably altered aortic sinus atherosclerotic plaque composition. Flavonoid intervention
enhanced energy expenditure, despite promoting a modest increase in food consumption during the active time
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and while maintaining similar ambulatory activity. In the
liver, fatty acid oxidation was increased, as were Cpt1a and
Pgc1a expression, suggesting enhanced fat mobilization. In
white adipose tissue, there were no consistent effects on
browning genes in visceral or subcutaneous depots and no
enhancement of browning genes in BAT, suggesting a nonbrowning mechanism of enhanced energy expenditure
and reduced adiposity. Although atherosclerotic lesion size
was unaffected, the improvements in metabolic parameters
with flavonoid intervention correlated with a reduction in
circulating monocytes and reduced macrophage content
in established atherosclerotic lesions, characteristics consistent with atherosclerosis regression (22).
Changes in food consumption can result from the effects of dietary components or drugs on behavior, satiety,
or energy balance, which in turn alter metabolic regulation, including adipose tissue metabolism (30). Consistent
with previously reported prevention studies, addition of
flavonoids to the HFHC diet did not decrease caloric intake as measured in standard caging (13–16). Studies from
other laboratories have reported reduced caloric intake in

Fig. 8. Intervention with citrus flavonoids prevents further elevation in blood monocytes. Ldlr/ mice were fed a HFHC diet for 12 weeks.
Subsequently the same mice were treated with flavonoids added to the HFHC diet for an additional 12 weeks. Peripheral blood mononuclear
cells (PBMCs) were isolated and stained for monocyte and neutrophil markers. A: Percent PBMCs that were Ly6Chi monocytes (n = 9–10 per
group). B: Percent of PBMCs that were Ly6Clo monocytes (n = 9–10 per group). C: Percent of PBMCs that were both Ly6Chi and Ly6Clo
monocytes. D: Percent of PBMCs that were neutrophils. E: Representative flow cytometric pseudocolor plots show monocytes and neutrophil
populations from each dietary group. Data represent the mean ± SEM. Different letters are statistically different by ANOVA with post hoc
Tukey test (P < 0.05). Nar, naringenin; Nob, nobiletin; N.S., not significant.

high-fat-fed mice with naringenin intervention, leading to
decreased body weight and adiposity (36), an effect likely
attributed to a taste aversion to the compound when administered in the food. In the present study, taste aversion
was mitigated by starting intervention at a low flavonoid
dose, which was slowly increased to the final dose over the
first week of intervention. Thus, food intake did not drop
precipitously, which would in itself cause weight loss. In
metabolic cage studies, we unexpectedly identified a small
(0.5 g/day) but significant increase in caloric consumption during the dark cycle in both naringenin- and nobiletin-treated mice, at weeks 21–23, near the end of the
intervention. Despite this small increase, intervention with
both flavonoids induced weight loss, decreased adiposity,
and improved metabolic indices, implying the molecular
mechanism for the flavonoid effects was not related to suppressed food intake (30). The reasons underlying the flavonoid-induced increase in caloric intake during the dark
cycle is not well understood, but may be related to a mild
starvation response resulting from increased energy expenditure. Pair-feeding experiments would help to confirm
and further understand this observation.
Naringenin intervention has previously been studied in
ovariectomized female C57BL/6J mice to assess its impact
on postmenopausal metabolic dysfunction (36, 37). In
chow-fed ovariectomized mice at a normal body weight, intervention by the addition of naringenin to chow prevented
weight gain while promoting modest weight loss, reduced
adiposity, and improved glucose homeostasis, accompanied by a reduction in caloric intake (36). When the same

ovariectomized mice were fed a high-fat diet, intervention
with the addition of naringenin to the high-fat diet prevented further weight gain and adiposity, while increasing
ambulatory activity, with no change in energy expenditure
(37). In our male Ldlr/ mice fed a high-fat diet, intervention with either flavonoid also decreased body weight and
adiposity, but was due to an increase in ANCOVA-adjusted
energy expenditure, with no change in ambulatory activity
and despite a small increase in caloric intake. Ambulatory
activity was lower in treated postmenopausal mice compared
with our flavonoid-intervention in Ldlr/ mice, which
might be attributed to postmenopausal sarcopenia. It is
possible that the discrepancy in activity results could be
due to differences in age and sex of the two models. The
lack of effect of flavonoid intervention on activity is consistent with our previous prevention studies in high-fat-fed
Ldlr/ mice treated with both naringenin and nobiletin
(15, 16). Experiments in age-matched female Ldlr/ mice
would help to further understand this observation.
Hypercholesterolemia, hyperglycemia, obesity, and, more
specifically, adipose tissue inflammation are all independent risk factors for leukocytosis, which can contribute
to accelerated atherosclerosis (32, 38, 39). In the present
study, intervention with either naringenin or nobiletin reduced atherosclerotic lesion macrophage content, consistent
with plaque regression. Reduced monocyte recruitment to
atherosclerotic plaques is characteristic of atherosclerosis
regression (21, 34). While trafficking kinetics to determine
the contribution of monocyte recruitment to the reduced
lesion macrophage content were not performed, leukocyte
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levels in the circulation were quantitated. Intervention with
naringenin or nobiletin prevented any further increase in
circulating Ly6Chi monocytes, known to be the precursor
of lesion macrophages (35). We also showed that intervention with chow induced a more notable, but not significant,
reduction from baseline in blood Ly6Chi monocytes compared with flavonoid intervention, but this did not translate into a reduction in circulating total monocytes. This
chow-alone intervention effect is consistent with previous
regression studies in high-fat-fed Ldlr/ mice (32), but not
studies in high-fat-fed Ldlr/ mice in which the chow intervention was coupled to hepatic Mttp deletion, which resulted in more rapid regression and a large reduction in
circulating monocytes (33). It is possible that interventions
with dietary flavonoids plus HFHC or chow alone were not
strong enough or long enough in duration to achieve
larger significant reductions in circulating monocytes (32,
33). In addition, neither flavonoid nor chow intervention
completely corrected hypercholesterolemia, thereby restricting a more robust reduction in myelopoiesis (38).
Furthermore, we used Ldlr/ mice, which develop more
modest monocytosis compared with Apoe/ mice in response to a high-fat diet, which would make the effects of
naringenin or nobiletin intervention more subtle, especially considering the incomplete correction of metabolic
dysfunction (29).
The mechanism(s) through which either naringenin or
nobiletin regulate energy expenditure, lipid metabolism,
and insulin sensitivity are not completely understood. Previous in vitro studies demonstrated that both naringenin
and nobiletin activate insulin signaling independent of the
insulin receptor or insulin receptor substrate (16, 40). Additionally, in high-fat-fed Ldlr/ mice, both naringenin
and nobiletin upregulated Pcg1a- and Cpt1a-mediated hepatic fatty acid oxidation, independent of peroxisomal proliferation, and suppressed Srebp1c-mediated fatty acid
synthesis (15, 16). The upstream mechanism(s) governing
these effects have remained somewhat elusive. The hormone-like fibroblast growth factor 21 elicits similar metabolic improvements as naringenin when given exogenously
to mice, but naringenin prevented metabolic dysfunction
and obesity in high-fat-fed Fgf21/ mice to the same extent as in wild-type mice (13). In short-term treatment of
Ob/Ob mice, naringenin supplementation to a low-fat diet
reversed hyperlipidemia, attenuated body weight, and improved hepatic steatosis and insulin sensitivity, indicating
that the naringenin effect was independent of leptin deficiency (13). This suggests that, unlike other natural compounds, such as celastrol and withaferin A, naringenin does
not work through enhancing leptin sensitivity (41, 42).
Alternatively, celastrol has also been shown to prevent weight
gain and improve metabolic dysfunction through activation of the heat shock factor 1-PGC1 axis in adipose tissue
and muscle, but not liver (43), more similar to, but not
identical to, the hepatic effects of naringenin or nobiletin.
Recent studies revealed that the addition of naringenin
plus apigenin (a related flavonoid) to a high-fat diet prevented the exacerbated rebound in body weight in mice,
when rechallenged with a high-fat diet following a period
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of chow-induced weight loss (44). Celastrol or a leptin-sensitizing antagonist did not mitigate weight rebound. Flavonoid treatment replaced the persistent high-fat diet-induced
loss of microbiome-derived flavonoid availability, resulting
in increased energy expenditure and upregulation of Ucp1
expression in BAT (44). In prevention models, we have
shown that naringenin modestly increases Ucp1 expression
in iWAT (13); but in the present study, we saw no effect
with either naringenin or nobiletin on iWAT or BAT Ucp1
expression. Additionally, we reported no change with nobiletin treatment on nonshivering thermogenesis; however,
experiments were not conducted at thermoneutrality (16).
This suggests that flavonoid-mediated enhanced browning
may not be the mechanism through which citrus flavonoids exert their anti-obesity effects. It is possible that the
browning effect of flavonoids in the weight cycling mouse
model was apigenin specific. Nobiletin, but not naringenin, has been shown to enhance the amplitude of circadian rhythms, specifically in obese mice (45). In our
previous studies, we have not observed any differences in
the effects of either naringenin or nobiletin treatment
aside from potency. Nobiletin is 10 times more potent
than naringenin, which is reflected in its lower effective
dose (0.3% vs. 3% of diet) (15, 16). It is possible that naringenin may also enhance clock sensitivity and that differences in dosing and administration may be responsible for
the discrepancy in results between naringenin and nobiletin
(15, 45).
In the present study, we tested one protocol of induction
and intervention times, 12 weeks induction with a HFHC
diet followed by 12 weeks intervention with either citrus
flavonoid supplemented to the HFHC diet. These timelines were chosen based on atherosclerosis regression
models in the literature and are similar to other dietary
flavonoid-intervention timelines (21, 36, 37). Twelve weeks
of HFHC induction was sufficient time to induce moderate
obesity, significant hyperlipidemia, moderate insulin resistance, hepatic steatosis, and intermediate atherosclerosis.
Twelve weeks intervention was sufficient to completely improve obesity and insulin resistance, but moderate hyperlipidemia and hepatic steatosis persisted, resulting in
improvements in lesion morphology, but no regression of
plaque size. This raises the intriguing possibility that a longer duration of flavonoid intervention would result in
greater resolution of these disorders. It would be of interest
to test different intervention durations and potentially longer induction periods to test the limits of flavonoid intervention on the resolution of diet-induced obesity, metabolic
syndrome, and atherosclerosis.
A number of human studies using purified citrus flavonoids have demonstrated improvements in plasma lipids,
glucose metabolism, and obesity [reviewed in (11)]. However, results were modest and inconsistencies between
studies and considerable inter-patient variation were observed. Bioavailability of flavonoids is low, especially in humans; metabolism of flavonoids differs between subjects
and differences in the enteric microflora may be responsible
for considerable inter-individual variability in absorption
and pharmacokinetic parameters (11). Larger controlled

human studies are required to assess dose, bioavailability,
efficacy, and safety for therapeutic development.
In summary, we have shown that intervention by the
addition of either of the citrus flavonoids, naringenin or
nobiletin, to a high-fat diet in obese mice reverses weight
gain and adiposity similar to intervention with chow, without reducing food intake. Mice treated with naringenin or
nobiletin consume more calories, but expend more energy
without increased ambulatory activity. Flavonoid-treated
mice regain insulin sensitivity and reverse hyperinsulinemia
completely. Plasma lipids are decreased and hepatic fatty
acid oxidation is increased resulting in reduced hepatic lipids. Collectively these improvements in atherogenic risk
factors did not result in lesion contraction, but improved
lesion morphology, most notably reduced lesion macrophage content, consistent with early stages of atherosclerosis
regression. These studies highlight the potential therapeutic utility of either naringenin or nobiletin, especially in the
context of existing obesity and metabolic dysfunction.
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